Atorlip 10: Effective LDL Cholesterol Management for Cardiovascular Health
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.79 | $47.30 (0%) | 🛒 Add to cart |
| 90 | $0.73 | $70.95 $65.36 (8%) | 🛒 Add to cart |
| 120 | $0.70 | $94.60 $83.42 (12%) | 🛒 Add to cart |
| 180 | $0.66 | $141.90 $119.54 (16%) | 🛒 Add to cart |
| 270 | $0.64 | $212.85 $172.86 (19%) | 🛒 Add to cart |
| 360 | $0.63
Best per pill | $283.80 $227.04 (20%) | 🛒 Add to cart |
Atorlip 10 contains atorvastatin calcium, a potent lipid-lowering medication belonging to the statin class. It is indicated as an adjunct to diet and lifestyle modifications for the management of hypercholesterolemia and mixed dyslipidemia. By competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, Atorlip 10 significantly reduces low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and triglycerides while moderately increasing high-density lipoprotein cholesterol (HDL-C). This comprehensive pharmacological profile supports its role in primary and secondary prevention of atherosclerotic cardiovascular disease. Clinical evidence confirms its efficacy in reducing the risk of myocardial infarction, stroke, and revascularization procedures in appropriate patient populations.
Features
- Contains 10 mg of atorvastatin (as calcium salt) per tablet
- White, oval, film-coated tablets debossed with manufacturer identification
- Available in blister packs of 10, 30, or 90 tablets
- Requires prescription-only dispensing
- Manufactured under strict GMP compliance
- Thermo-stable formulation with 24-month shelf life
- Bioequivalent to reference listed drug
- Vegetarian-friendly excipients (varies by manufacturer)
Benefits
- Reduces LDL cholesterol by 35-50% at the 10 mg dosage
- Lowers cardiovascular event risk in patients with multiple risk factors
- Improves endothelial function and stabilizes atherosclerotic plaques
- Decreases triglyceride levels by 20-40% in hypertriglyceridemic patients
- Provides 24-hour lipid-lowering effect with once-daily dosing
- Demonstrates proven mortality benefit in secondary prevention
Common use
Atorlip 10 is primarily prescribed for patients requiring moderate-intensity statin therapy. Typical candidates include adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia who have not achieved target LDL-C levels through dietary modifications alone. It is also indicated for cardiovascular risk reduction in patients with type 2 diabetes and other risk factors, as well as for preventing cardiovascular events in patients with established cardiovascular disease. The medication may be used as monotherapy or in combination with other lipid-lowering agents under specialist supervision.
Dosage and direction
The recommended starting dose is 10 mg once daily, which may be adjusted based on lipid response and tolerability after 2-4 weeks. Administration may occur at any time of day, with or without food, though consistency in timing is advised. Tablets should be swallowed whole with water and not crushed or chewed. Dosage may be increased to a maximum of 80 mg daily for patients requiring more aggressive LDL-C reduction. Renal impairment typically requires no dosage adjustment, while hepatic impairment may necessitate lower doses or alternative therapy. Elderly patients generally require no specific dosage modifications.
Precautions
Liver function tests should be performed before initiation and periodically during treatment. Patients should report unexplained muscle pain, tenderness, or weakness immediately. Blood glucose levels should be monitored in diabetic patients due to possible modest increases in HbA1c and fasting serum glucose. Caution is advised in patients consuming substantial quantities of alcohol or with history of liver disease. The medication should be temporarily discontinued in patients experiencing major surgery, trauma, or severe metabolic disorders. Ophthalmological examination may be considered if visual changes occur.
Contraindications
Atorlip 10 is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal. It must not be used during pregnancy, lactation, or in women of childbearing potential not using adequate contraception. Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, HIV protease inhibitors) is contraindicated. Hypersensitivity to atorvastatin or any excipients in the formulation prohibits use. The medication is not indicated for pediatric patients or those with rare hereditary galactose intolerance.
Possible side effects
Common adverse reactions (≥1/100 to <1/10) include headache, insomnia, nausea, diarrhea, dyspepsia, arthralgia, and myalgia. Uncommon effects (≥1/1,000 to <1/100) may consist of constipation, flatulence, dizziness, rash, pruritus, and asthenia. Rare side effects (≥1/10,000 to <1/1,000) include hepatitis, pancreatitis, peripheral neuropathy, memory impairment, and gynecomastia. Very rare events (<1/10,000) include rhabdomyolysis with renal dysfunction, lupus-like syndrome, and tendon rupture. Most side effects are mild and transient, often resolving with continued therapy or dosage adjustment.
Drug interaction
Atorvastatin is metabolized primarily by CYP3A4, resulting in significant interactions with potent inhibitors (e.g., cyclosporine, telithromycin) which may increase statin exposure and myopathy risk. Concomitant use with gemfibrozil increases rhabdomyolysis risk and should generally be avoided. Bile acid sequestrants may reduce atorvastatin bioavailability and should be administered at least 2 hours apart. Moderate interactions occur with amiodarone, verapamil, diltiazem, and fusidic acid. Warfarin coadministration may potentiate anticoagulant effect requiring more frequent INR monitoring. Oral contraceptives containing ethinyl estradiol and norgestrel may have increased AUC when coadministered.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If the next day’s dose is approaching, the missed dose should be skipped and the regular dosing schedule resumed. Double dosing to make up for a missed dose is not recommended. Patients should maintain their regular dosing pattern and not take extra tablets to compensate for missed doses. Consistent daily administration provides optimal lipid-lowering effects, though occasional missed doses are unlikely to significantly impact long-term cholesterol control.
Overdose
No specific antidote exists for atorvastatin overdose. Symptomatic and supportive measures should be instituted based on clinical presentation. Gastric lavage may be considered if performed soon after ingestion. Liver function tests and CPK levels should be monitored. Rhabdomyolysis and acute renal failure are potential serious consequences of massive overdose requiring appropriate hydration and possibly alkalinization of urine. Hemodialysis is unlikely to be beneficial due to high protein binding. Medical toxicology consultation is recommended for significant overdoses.
Storage
Store below 30°C in the original packaging to protect from light and moisture. Keep blister strips sealed until immediately before use. Do not refrigerate or freeze. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of unused or expired medication through pharmacy take-back programs rather than flushing or household trash disposal.
Disclaimer
This information serves educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or making changes to existing treatment. Individual patient responses may vary, and therapeutic decisions should be based on comprehensive clinical assessment. The manufacturer and distributors assume no liability for inaccurate information or improper use.
Reviews
Clinical studies demonstrate that atorvastatin 10 mg achieves LDL-C reduction goals in approximately 60-70% of moderate-risk patients. Meta-analyses of outcome trials show consistent 20-30% relative risk reduction in major cardiovascular events. Real-world evidence supports good tolerability with discontinuation rates due to adverse effects typically below 5%. Patients report satisfaction with once-daily dosing convenience and measurable improvements in lipid parameters. Some users note mild gastrointestinal symptoms during initial weeks that often resolve with continued use. Healthcare professionals appreciate the predictable pharmacokinetics and extensive evidence base supporting its use in diverse populations.